TABLE IV.

Survival and secondary analyses in neutropenic patients

Variable		Neutropenia		p Value
		Yes	Yes
		g-csf (n=16)	No g-csf (n=44)
Index to progression (days)	Median	323a	294b	0.47
	iqr	317–380	127–427
Survival (days)	Median	613c	487d	0.48
	iqr	342–1070	295–796
folfiri cycles (n)	Mean	19.2	16.4	0.52
	95% cl	10.0, 28.3	12.2, 20.6
Treatment delay for any reason (days)	Mean	88.9	56.3	0.27
	95% cl	24.4, 153.4	28.3, 84.4
Proportion of treatment reduction for any reason (%)	Mean	8.5	9.5	0.33
	95% cl	0.06, 0.57	0.30, 0.61
Hospital admissions for any reason (n)	Mean	0.44	0.39	0.80
	95% cl	0.05, 0.82	0.19, 0.58
Infections for any reason (n)	Mean	0.87	0.48	0.19
	95% cl	0, 1.78	0.27, 0.68
Neutropenic episodes (n)	Mean	2.06	2.29	0.65
	95% cl	1.32, 2.80	1.73, 2.86
Dose delays for any reason (n)	Mean	2.06	2.18	0.82
	95% cl	1.32, 2.80	1.60, 2.76
Treatment delay because of infection or neutropenia (days)	Mean	25.2	23.8	0.84
	95% cl	14.4, 36.1	15.8, 31.8
Reduction in folfiri dose because of infection or neutropenia (%)	Mean	4.7	6.8	0.45
	95% cl	0.2, 9.2	3.8, 9.8
Treatment delay because of neutropenia (days)	Mean	21.3	21.4	0.99
	95% cl	11.0, 31.6	13.8, 29.0
Neutropenic episodes (n)	Mean	2.06	2.29	0.65
	95% cl	1.32, 2.80	1.73, 2.86

^aOf 16 patients, 9 had documented progression.

^bOf 44 patients, 31 experienced progression during the study period.

^cOf 16 patients, 7 died before the study period ended.

^dOf 44 patients, 25 died before the study period ended.